The initiatives will also enable the Company to significantly reduce its
Ticker Symbol: TOS/TSX
Shares Outstanding: 47,863,402
QUEBEC CITY, June 5 /CNW Telbec/ - TSO3 Inc. ("TSO3") (TSX: TOS)
announces that it is realigning resources and re-focusing marketing activities
to enhance its rate of market penetration and sales growth for 2008 and
beyond. These initiatives will also allow the Company to significantly reduce
its operating expenses rate thanks to more efficient use of sales and
Initiatives impact four areas: (1) market segmentation of the primary
North American hospital market, using a contracted specialized US marketing
firm in conjunction with direct selling resources; (2) realign sales resources
to more effectively focus its senior sales management team on targets in the
pipeline and sales leads; (3) reducing cash burn rate for 2008 by
$2.1 million; (4) assessing and prioritizing R&D projects with resource
additions as needed. Additionally, TSO3 will be analysing other near term
sales opportunities for its 125L Ozone Sterilizer by evaluating other
territories or market sectors, such as other countries and medical device
companies, which offer pre-sterilized products to the market.
TSO3 is already seeing early indications of momentum from these recent
initiatives with several target accounts pending purchase decisions.
"These new measures should allow us to generate sales momentum to achieve
our expected sales forecast, while attaining a net effect of cash burn rate
reduction of $2.1M for the remainder of the year", stated W. Barry McDonald,
Interim CEO for TSO3. "This re-focusing and realigning is being done with the
intent of maximising the very capable sales resources that we have on board at
management level, to generate sales in the very short term and ensure business
growth in 2008 and beyond".
TSO3 plans to give an update on the progress of these initiatives and
provide further quantitative financial information on its reduced operating
expenses, on or before its next quarterly release in early August. Moreover,
from now on, the sales realized by the Company during the normal course of its
operations will be disclosed within the quarterly results report.
TSO3 will host a Conference Call at 11:00 A.M. (ET), on June 6, 2008.
Analysts and institutional investors are invited to participate. The numbers
to dial for access are 514 807-8791 (Montréal area), 416 644-3415 (Toronto
area) or the toll-free number 1 800 733-7560.
Journalists and other interested parties may listen to the live Webcast
of the Conference Call accessible via TSO3's Website at: www.tso3.com. The
Webcast will be archived for 90 days.
TSO3, founded in Québec City in 1998, specializes in the research and
development of innovative, high-performance medical instrument sterilization
technology with high commercial potential. The Company's first product, the
125L Ozone Sterilizer, is designed for sterile processing centers in the
In contrast to other methods used, the ozone sterilization process
developed and patented by TSO3 meets all standards required by the evolution
in sterilization needs, which are: significant costs savings, increased safety
for patients and hospital staff, and a "green" environmentally safe process.
The Company believes that its technology represents an advantageous
replacement solution to other low temperature sterilization processes
currently used in hospitals.
The 125L Ozone Sterilizer is cleared for commercialization by the US Food
and Drug Administration and by Health Canada. TSO3 is in commercialization
phase for this first product since 2006.
For more information about TSO3, visit the Company's Web site at
The statements in this release and oral statements made by
representatives of TSO3 relating to matters that are not historical facts
(including, without limitation, those regarding the timing or outcome of any
financing undertaken by TSO3) are forward-looking statements that involve
certain risks, uncertainties and hypotheses, including, but not limited to,
general business and economic conditions, the condition of the financial
markets, the ability of TSO3 to obtain financing on favourable terms and other
risks and uncertainties.
The TSX has neither approved nor disapproved the information contained
herein and accepts no responsibility for it.
For further information:
For further information: Marc Boisjoli, CFO, (418) 651-0003, ext. 228,
email@example.com; Frédéric Tremblay, HKDP, (514) 395-0375, ext. 234; Source: